BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2022 11:52:43 AM | Browse: 203 | Download: 415
|
Received |
|
2022-06-28 11:49 |
|
Peer-Review Started |
|
2022-06-28 11:51 |
|
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-07-14 03:35 |
|
Revised |
|
2022-07-16 09:12 |
|
Second Decision |
|
2022-08-17 03:16 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-08-17 21:11 |
|
Articles in Press |
|
2022-08-17 21:11 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-08-30 20:04 |
|
Publish the Manuscript Online |
|
2022-09-16 11:52 |
ISSN |
2307-8960 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Review |
Article Title |
Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update
|
Manuscript Source |
Invited Manuscript |
All Author List |
Efstathios Theodoros Pavlidis and Theodoros Efstathios Pavlidis |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Theodoros Efstathios Pavlidis, Doctor, PhD, Chief Doctor, Director, Full Professor, Surgeon, Department of 2nd Surgical Propedeutic, Aristotle University of Thessaloniki, School of Medicine, Konstantinoupoleos 49, Thessaloniki 54642, Greece. pavlidth@auth.gr |
Key Words |
Gastrointestinal neuroendocrine tumors; Neuroendocrine neoplasms; Mixed NEN; Neuroendocrine carcinoma; APUD cells; Carcinoids; Somatostatin analogs |
Core Tip |
Novel diagnostic modalities, including imaging, biomarkers and molecular factors such as liquid biopsy based on mRNA and NETest index, including 51 genes, have changed diagnosis and follow-up. Current available therapeutic options for gastrointestinal neuroendocrine tumors open new horizons promising better results. Surgery remains the cornerstone for resectable disease, but drug therapies, mainly somatostatin analogs, somatostatin receptor antagonists, molecular-targeted drugs and new chemotherapeutic agents are important in the palliative treatment of inoperable or recurrent cases. Advances in genomic profiling and endoscopic intervention could individualize management options. |
Publish Date |
2022-09-16 11:52 |
Citation |
Pavlidis ET, Pavlidis TE. Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update. World J Clin Cases 2022; 10(27): 9573-9587 |
URL |
https://www.wjgnet.com/2307-8960/full/v10/i27/9573.htm |
DOI |
https://dx.doi.org/10.12998/wjcc.v10.i27.9573 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345